Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04985955 | A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3 | PHASE1 | COMPLETED | 12 | — | — | Jul 30, 2021 | Sep 21, 2021 | Feb 3, 2025 | 1 | Belgium |
Number of participants with presence and size of induration in active versus control at the Candin injection site compared to the intra-individual saline control injection site approximately 48 hours after Candin challenge will be reported.
| Arm | Type | Description |
|---|---|---|
| Candin + Tofacitinib | EXPERIMENTAL | Participants will receive a single dose of Candin injection on forearm of 1 arm along with a saline solution injection of 0.9 percent (%) sodium chloride (NaCl) on the opposite forearm on Day 3 and oral dose of tofacitinib for 5 days. |
| Candin Challenge | NO_INTERVENTION | All participants will receive a single dose of Candin injection on forearm of 1 arm along with a saline solution injection of 0.9% NaCl on the opposite forearm on Day 3. |
| Name | Type | Description |
|---|---|---|
| Tofacitinib | DRUG | Tofacitinib tablet will be administered orally. |
Inclusion Criteria: * Have a body mass index (BMI) between 18 and 30 kilograms per meter square (kg/m\^2) (BMI = weight/height\^2), inclusive, and a body weight of no less than 50 kilograms (kg) * Healthy on the basis of physical examination, medical history, and vital signs performed at screening....